Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B

Figure 1 Cumulative probabilities of virologic breakthrough in the two treatment groups.

Figure 2 A comparison of the cumulative probabilities of virologic response and viral breakthrough according to different treatment strategies using adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. Groups A and B represent the patients who followed or violated the roadmap treatment strategy, respectively; Group C stands for those treated by adding adefovir dipivoxil in addition to ongoing lamivudine therapy. The roadmap treatment strategy was supposed to initiate adefovir monotherapy first and then add lamivudine when serum HBV DNA levels were ≥ 60 IU/mL at six months of treatment. A: There were significant differences in the cumulative probabilities of virologic responses between any two treatment groups (P < 0.001); B: The cumulative probability of virologic breakthrough was significantly lower in group C than in group B (P = 0.002) but not lower than group A (P = 0.114). However, there was a significant difference between groups C and A in the multivariate Cox’s regression model (Table 3).